Granted Patent B2

US 12,196,757 · App. 17/563,279 · Granted Jan 14, 2025

Inventors: Benjamin Katchman (Tempe, AZ); Karen Anderson (Scottsdale, AZ); Garrick Wallstrom (Mesa, AZ); Joshua LaBaer (Chandler, AZ); Daniel Cramer (Chestnut Hill, MA)

Assignees: ARIZONA BOARD OF REGENTS ON BEHALF OF ARIZONA STATE UNIVERSITY; THE BRIGHAM AND WOMEN'S HOSPITAL, INC.

G01N33/57449G01N2800/60

Abstract

Claims (12)

1. A method comprising the steps of:

contacting a fluid from a patient that contains a tumor antigen-associated autoantibody (TAAb) with a panel of antigens, thereby forming an antigen/TAAb complex in vitro if said TAAb binds an antigen on said panel, wherein said panel of antigens consists of cancer/testis antigen 2 (CTAG2), cellular tumor antigen p53 (p53), poliovirus receptor (PVR), diphosphoinositol polyphosphate phosphohydrolase 3-beta (NUDT11), intercellular adhesion molecule 3 (ICAM3), E3 ubiquitin-protein ligase TRIM39 (TRIM39), serine/threonine/tyrosine-interacting-like protein 1 (STYXL1), Pro-opiomelanocortin (POMC), serine/threonine-protein kinase Kist (UHMK1), kinase suppressor of Ras 1 (KSR1), and nuclear RNA export factor 3 (NXF3), wherein antigens in the panel are linked to a solid support; and

detecting whether each antigen in the panel of antigens forms an antigen/TAAb complex.

2. The method of claim 1 , wherein said panel of antigens comprises a Nucleic Acid Protein Programmable Array (NAPPA).

3. A method for administering a diagnostic procedure or a therapeutically effective treatment following early stage ovarian cancer detection in a patient, comprising the steps of:

(a) contacting a fluid that contains immunoglobulins from said patient with a substrate comprising biomarkers, wherein the substrate comprises a solid support, the biomarkers consisting of ICAM3, CTAG2, p53, STYXL1, PVR, POMC, NUDT11, TRIM39, UHMK1, KSR1, and NXF3;

(b) detecting whether each biomarker is bound by the patient's immunoglobulins; and

(c) administering a diagnostic procedure or a therapeutically effective treatment based on the detecting in step (b).

4. The method of claim 3 , further comprising administering a therapeutically effective treatment for said patient, the treatment selected from the group consisting of a surgical intervention, a chemotherapeutic intervention, and a radiotherapeutic intervention, if two or more biomarkers are detected.

5. The method of claim 1 , wherein said solid support comprises a 96-well plate.

6. The method of claim 3 , wherein the solid support comprises a 96-well plate.

7. The method of claim 3 , wherein the substrate comprising biomarkers comprises a Nucleic Acid Protein Programmable Array (NAPPA).

Assignments (2)

Continuity (3)

References Cited (71)